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ACR = American College of Rheumatology; CIA = collagen induced arthritis; CRP = C-reactive protein; IL = interleukin; sIL-6Rα = soluble IL-6
receptor; sJIA = systemic onset juvenile idiopathic arthritis; RA = rheumatoid arthritis.
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Abstract
IL-6 is a pleiotropic cytokine involved in both the initiation and the
maintenance of the inflammatory and immunologic responses in
certain autoimmune diseases. Blocking of these two comple-
mentary functions of IL-6 may confer additive, or even unique,
benefits to the patient. The levels of both IL-6 and its soluble
receptor (sIL-6Rα) are elevated to various degrees in many
rheumatic diseases. IL-6 blockade has been shown to be beneficial
both in experimental models and in human disease, and inhibition
of IL-6 signaling with a molecule such as tocilizumab could prevent
or reverse some of the complications typically associated with
rheumatic diseases. 
Introduction
IL-6 is a pleiotropic cytokine that has actions on a host of
biologic systems. Because of the broad spectrum of
activities, it has been suggested that IL-6 may contribute to
the pathophysiology of inflammatory arthritis. High levels of
IL-6 are produced in the joints of patients with rheumatoid
arthritis (RA), and large quantities can be detected in their
serum. These findings have contributed to the view that
increased secretion of IL-6 may be responsible for local and
systemic signs and symptoms in patients with RA. IL-6 acts
as a stimulator of both B and T cell functions and also
promotes proliferation of plasmablasts during their final
stages of maturation into immunoglobulin producing plasma
cells [1]. Based on its multiple stimulatory effects on cells of
the immune system, as well as on vascular endothelial cells,
osteoclasts and synovial fibroblasts, it is believed its excess
plays a pathogenic role in the development of the inflam-
matory manifestations of RA. In this regard, IL-6, in
conjunction with the soluble IL-6 receptor (sIL-6Rα), has
been shown to activate endothelial cell production of a
subset of chemokines and to upregulate expression of
adhesion molecules, thereby contributing directly to
recruitment of leukocytes at inflammatorysites [2]. In addition,
IL-6 can stimulate synoviocyte proliferation [3] and osteoclast
maturation and activation [4], therefore suggesting a role in
synovial pannus formation and in bone resorption in inflamed
joints. IL-6 is also known to be an endogenous pyrogen [5]
and is the major cytokine inducer of acute phase response
genes [6]. Because of this panoply of activities, IL-6 is
thought to play a critical role in synovial and systemic
inflammation in RA.
Animal models
Genetically manipulated mice have been useful in identifying
the role of specific cytokines in models of human disease. In
most circumstances, ablation of a single cytokine is
compatible with normal life [7], affording the opportunity to
examine the role of that specific cytokine in disease
pathogenesis. There are data from a large range of rodent
models of arthritis suggesting that enhanced production of
IL-6 is characteristic of inflammatory arthritis in mice [8].
Collagen induced arthritis (CIA) is a murine model of human
inflammatory arthritis that is associated with increased
production of IL-6. In comparison with wild-type mice, IL-6
knockout mice were completely protected from CIA, clearly
indicating the central role of IL-6 in this model. Protection
was associated with reduced antibody response to type II
collagen and absence of inflammatory cells and tissue
damage in knee joints [9]. CIA was fully restored to IL-6
knockout mice by administration of a combination of IL-6 and
its soluble receptor. Notably, intra-articular administration of
IL-6 itself was insufficient to reconstitute arthritis in these
mice. However, a sIL-6Rα/IL-6 fusion protein reconstituted
disease activity [10]. This finding is explained by the
observation that many cells within the inflamed joint do not
express the transmembrane IL-6R, but they can be
stimulated by an IL-6/IL-6R complex that can interact with
the signalling portion of the IL-6R, gp130 (CD130), which is
expressed by all cells.
Importantly, although high IL-6 concentrations have been
documented in serum and synovial fluids of patients with
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various arthritides, cell types resident to the joint
(chondrocytes, synoviocytes, fibroblasts and endothelial
cells) lack expression of IL-6R [11]. Consequently, these cells
are unresponsive to IL-6 itself. IL-6 complexed to its soluble
receptor may therefore represent the major mechanism by
which IL-6 elicits its effect during arthritis. Analyses of
synovial fluid from arthritic patients have shown that increases
in sIL-6Rα correlate with the extent of joint destruction and
correspond to more advanced stages of RA [3,12]. In this
respect, in vitro studies have implicated involvement of sIL-
6Rα in synovial proliferation, bone resorption and other
inflammatory processes [3,12].
Development of interleukin-6 blockade as a
therapy
Results from studies of murine models support the
conclusion that IL-6 is a promising target for effective thera-
peutic intervention in RA. A study by Takagi and coworkers
[13] reported findings supporting this conclusion; they found
that the rat anti-mouse IL-6 receptor (anti-IL-6R) monoclonal
antibody MR16-1 significantly reduced the development of
CIA by suppressing IL-6 signal transduction.
Murine monoclonal antibodies are not suitable for develop-
ment as therapeutic agents in humans because of their short
half-lives and the probable development of neutralizing
antibodies due to the immunogenicity of the mouse protein.
As a result, a humanized anti-IL-6 receptor monoclonal anti-
body, tocilizumab, was developed in a collaboration between
the Chugai Pharmaceutical Co., Ltd (Tokyo, Japan; now a
member of the F Hoffmann-La Roche Ltd Group) and the
Medical Research Council Collaborative Centre (London,
UK) [14,15]. This antibody was previously referred to as
MRA. As proof of principle, in an examination of the impact of
tocilizumab on CIA in cynomolgus monkeys, blocking the
activity of IL-6 with tocilizumab suppressed CIA, inhibiting
clinical, histological and radiographic manifestations of joint
damage [16].
As discussed above, there is considerable evidence that IL-6
plays an important role in rheumatoid inflammation. For example,
serum IL-6 levels are dramatically elevated in RA patients, and
this elevation can be directly correlated with clinical and
laboratory indices of disease activity, such as C-reactive protein
(CRP) [17]. Therefore, the impact of tocilizumab in RA patients
was examined in a phase I/II randomized, double blind, placebo
controlled, single dose escalation trial [18]. Disease modifying
antirheumatic drugs were withdrawn from patients enrolled in
the study for 1 month before tocilizumab treatment. The primary
end-point of the study was American College of Rheumatology
(ACR)20 response. As shown in Figure 1, at the higher doses of
tocilizumab 50% of patients achieved an ACR20 response
within 2 weeks. Responses from a single dose of tocilizumab in
the absence of concomitant disease modifying antirheumatic
drugs were sustained for about 8 weeks following
administration.
IL-6 blockade also appears to be efficacious in systemic
onset juvenile idiopathic arthritis (sJIA). Recently, data were
reported from a dose escalation trial conducted in children
with sJIA in which the administered dose was increased from
2 mg/kg to 4 mg/kg to 8 mg/kg given twice a month [19]. At
2 mg/kg there was a good response, as measured by the JIA
core set of improvement criteria, with 60% of patients
achieving 30% and 50% responses. When all the doses
were combined, more than 60% of patients achieved a 70%
response, which is indicative of the capacity of tocilizumab to
confer significant benefit in patients with sJIA (Figure 2).
Figure 1
Sustained ACR20 response to treatment with tocilizumab. ACR, American College of Rheumatology. *P = 0.023, **P = 0.002, §P = 0.008, and
†P = 0.043 versus placebo. Reprinted, with permission, from [18]. Copyright © 2002 American College of Rheumatology.Page 3 of 5
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Interleukin-6 blockade and other
manifestations of inflammatory arthritis
Apart from controlling the signs and symptoms of inflam-
matory arthritis, blockade of IL-6R signalling also exerted a
positive effect on a number of other manifestations of these
conditions. For example, in chronic diseases characterized by
increases in IL-6, a clear association with anaemia has been
shown [20]. In this regard, a negative correlation between
IL-6 and haemoglobin levels was reported in the geriatric
syndrome of frailty [21]. The inverse correlation between IL-6
and haemoglobin levels was not thought to be related to iron
deficiency [21]. Notably, in experimental animal and human
clinical studies,administration of IL-6 was associated with the
development of anaemia. Thus, treatment of patients with
cancer with IL-6 has led to a rapid decrease in haemoglobin
concentrations [22], and administration of IL-6 to rhesus
monkeys correlated with a decline in packed cell volume [23].
These studies support the link between a chronic increase in
IL-6 and development of anaemia. One possible explanation
for this finding relates to the action of the acute phase
reactant, hepcidin, which is produced by the liver in response
to IL-6 [24]. Hepcidin exerts a dual effect in that it interferes
with the release of iron from macrophages and interferes with
iron absorption. It is thought to be a central determinant of the
development of anaemia in chronic disease. That upregulation
of hepcidin is driven by IL-6 in inflammation was demonstrated
in vivo in experiments comparing the responses of wild-type
and IL-6 knockout mice [25]. Mice challenged with an
inflammatory stimulus exhibited a dramatic increase in hepatic
hepcidin mRNA and a decline in serum iron, whereas these
responses were absent in IL-6 knockout mice.
In diseases such as Castleman’s disease, normalization of
IL-6 levels is paralleled by resolution of anaemia [26]. This
was also observed in RA and sJIA patients treated with
tocilizumab [27,28]. In a multicentre, randomized clinical trial
in patients with established RA using multiple doses of
tocilizumab – the CHARISMA study (Chugai Humanized Anti-
human Recombinant Interleukin Six Monoclonal Antibody)
[26] – anaemia resolved within 2 weeks of administration of
tocilizumab. This demonstrates that overproduction of IL-6
contributes directly to the development of chronic anaemia
and that, by blocking the IL-6R, this can be reversed.
Another potential benefit of IL-6 blockade relates to the effect
of IL-6 on bone metabolism. Patients affected by RA and sJIA
often have systemic osteoporosis, independent of cortico-
steroid treatment [29]. Young sJIA patients are characterized
by stunted growth, and preliminary clinical studies using
tocilizumab in these patients have demonstrated significant
improvement in patient height, leading to catch-up growth
[27]. Bone abnormalities occur in diseases characterized by
high levels of IL-6 because IL-6 has pro-osteoclastic activity
and may also influence bone resorption [30].
IL-6 has also been speculated to play an important role in the
development of coronary artery disease through a number of
metabolic, endothelial and procoagulant mechanisms [31,32].
Prospective studies of apparently healthy and high-risk
individuals indicate that increased levels of IL-6 [33,34] and
CRP [35,36] – a surrogate of IL-6 levels – are predictors of
cardiovascular mortality [33] and future myocardial infarction
[34]. Substantive interrelationships of circulating IL-6, CRP
and traditional risk factors have been described in women
[37]. The IL-6 level has been demonstrated to be a strong
independent marker of increased mortality in unstable
coronary artery disease and identifies patients who benefit
most from a strategy of early invasive management [38].
Although hypothetical, there is reason to suggest that
blockade of the IL-6 signalling pathway in patients with
inflammatory diseases characterized by IL-6 overproduction
may be of benefit to patients that have a very high risk for
coronary artery disease.
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Figure 2
Therapeutic efficacy of blocking IL-6 activity in sJIA. IL, interleukin; sJIA, systemic onset juvenile idiopathic arthritis. Reprinted, with permission, from
[19]. Copyright © 2005 American College of Rheumatology.Conclusion
Overall, it has been demonstrated that IL-6 is a major
contributor to the pathophysiology of inflammatory arthritis,
including RA and sJIA. Because of the central role played by
IL-6 in a number of manifestations of these inflammatory
diseases, IL-6 is a candidate target for therapeutic inhibition
as a novel approach to the treatment of RA, sJIA and perhaps
other related rheumatic diseases. IL-6 blockade has been
shown to be beneficial both in experimental models and in
human disease, and inhibition of IL-6 signalling with a
molecule such as tocilizumab could prevent or reverse some
of the complications typically associated with rheumatic
diseases. Additional studies will establish the role of
tocilizumab in therapy for rheumatic diseases.
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